Larson Financial Group
SPRY icon

Larson Financial Group’s ARS Pharmaceuticals SPRY Stock Holding History

Larson Financial Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$873 Sell
109
-147
-57% -$1.26K ﹤0.01% 3363
2026
Q1 		$2.06K Buy
256
+173
+208% +$1.66K ﹤0.01% 2956
2025
Q4 		$967 Buy
83
+79
+1,975% +$768 ﹤0.01% 2967
2025
Q3 		$40 Sell
4
-28
-88% -$402 ﹤0.01% 3365
2025
Q2 		$558 Buy
+32
New +$462 ﹤0.01% 2830

Other funds holding SPRY

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SR One Capital Management
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Larson Financial Group's SPRY Position: Q2 2026 in Review

Larson Financial Group reduced its ARS Pharmaceuticals (SPRY) stake by 57% in Q2 2026, selling an estimated $1.26K and leaving 109 shares worth $873. The position accounts for ﹤0.01% of the portfolio, ranked #3363.

Larson Financial Group first reported a position in SPRY in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.06K in Q1 2026. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Larson Financial Group held 109 shares of ARS Pharmaceuticals worth $873 as of Q2 2026.
  • Larson Financial Group sold 147 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.26K.
  • ARS Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3363 holding.
  • Larson Financial Group first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Larson Financial Group's ARS Pharmaceuticals position peaked at $2.06K in Q1 2026.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.